Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 7/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116526 | 0.91 | GBA1 (0.36) | ACHEMAOBGBA1HTR1A | |
| SCHEMBL2116637 | 0.85 | BCHE (0.35) | ACHEMAOBBCHEHTR1AKDM4E | |
| SCHEMBL2116170 | 0.84 | BCHE (0.38) | ACHEMAOBBCHEGBA1HTR1A | |
| SCHEMBL2118268 | 0.82 | HRH1 (0.37) | ACHEMAOBGBA1 | |
| SCHEMBL2115839 | 0.81 | BCHE (0.36) | ACHEMAOBBCHEGBA1HTR1A | |
| SCHEMBL2116525 | 0.75 | CYP2D6 (0.31) | BCHE | |
| SCHEMBL2116532 | 0.74 | ACHE (0.39) | ACHEMAOBBCHEHTR1AKDM4E | |
| SCHEMBL14652141 | 0.74 | ALDH1A1 (0.39) | BCHEKDM4EALDH1A1 | |
| SCHEMBL14519148 | 0.74 | ALDH1A1 (0.39) | BCHEKDM4EALDH1A1 | |
| SCHEMBL2116367 | 0.74 | GBA1 (0.36) | BCHEGBA1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | ACHE 3180/4885MAOB 643/4885BCHE 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.